BC
GCVRZ

Bartlett & Co’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Bartlett & Co’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$0 Hold
100
– – ﹤0.01% 961
2019
Q2 		$0 Hold
100
– – ﹤0.01% 825
2019
Q1 		$0 Hold
100
– – ﹤0.01% 771
2018
Q4 		$0 Hold
100
– – ﹤0.01% 727
2018
Q3 		$0 Hold
100
– – ﹤0.01% 746
2018
Q2 		$0 Buy
+100
New +$47 ﹤0.01% 788

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Bartlett & Co's GCVRZ Position: Q3 2019 in Review

Bartlett & Co held its Sanofi Contingent Value Rights (GCVRZ) position steady in Q3 2019 at 100 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #961.

Bartlett & Co first reported a position in GCVRZ in Q2 2018 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2019.

  • Bartlett & Co held 100 shares of Sanofi Contingent Value Rights worth $0 as of Q3 2019.
  • Bartlett & Co left its Sanofi Contingent Value Rights share count unchanged in Q3 2019.
  • Sanofi Contingent Value Rights made up ﹤0.01% of Bartlett & Co's portfolio in Q3 2019, its #961 holding.
  • Bartlett & Co first reported a position in Sanofi Contingent Value Rights in Q2 2018 and has held it in 6 quarters since.
  • 103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2019.

Based on Bartlett & Co's 13F filing for Q3 2019, filed 4 Nov 2019.